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Accumulation of CAMP in the human T-cell leukemia cell line Jurkat was stimulated by the adenosine ana- 
logue 5’-N-ethylcarboxamidoadenosine (NECA) and by prostaglandin E, (PGE,). Addition of two phorbol 
esters, PDiBu and TPA, markedly enhanced the NECA-stimulated accumulation of CAMP whereas the 
PGE,-stimulated CAMP accumulation was substantially reduced. The non-tumor-promoting phorbol ester, 
4a-PDD, had no effect on either NECA- or PGE,-stimulated CAMP accumulation. The ability of PDiBu 
to inhibit the effect of PGE, and to stimulate the effect of NECA remained in the presence a low concentra- 
tion of forskolin (0.3 PM), which per se increased both NECA- and PGE,-stimulated CAMP accumulation. 
Our results suggest hat the effect of PK-C-activating drugs on receptor-mediated CAMP accumulation is 
entirely dependent on which receptor is being stimulated 
Lymphocyte; Phorbol ester; Phosphorylation; Adenylate cyclase; Forskolin 
1. INTRODUCTION 
Activation of PK-C has been shown either to 
potentiate [l-4] or to inhibit receptor-stimulated 
accumulation of CAMP [5]. PK-C can be activated 
by stimulation with tumor-promoting phorbol 
esters, synthetic diacylglycerol derivatives and by 
receptor-mediated activation of phospholipase C 
leading to the formation of diacylglycerol from 
phosphatidylinositol [6,7]. It has been suggested 
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that the explanation of the PK-C enhancement of 
CAMP accumulation is that the guanine 
nucleotide-binding protein (Ni or Gi), which 
mediates inhibition of adenylate cyclase, is inac- 
tivated by phosphorylation [4,8,9], but there are 
probably also other mechanisms [3,8-lo]. For ex- 
ample, it was recently shown that purified PK-C 
can directly stimulate adenylate cyclase in mem- 
brane preparations from rat fat cells [ 151. 
We recently showed that activation of PK-C in 
the human T-cell leukemia cell line Jurkat marked- 
ly potentiated the CAMP response induced by 
adenosine receptor stimulation [ 121. By contrast, 
in the murine interleukin-2-dependent T-cell line 
CT6 both prostaglandin receptor-stimulated and 
basal levels of CAMP were reduced by IL-2 and 
phorbol ester, and by incubating membranes with 
semipurified PK-C [5]. By studying the effect of 
tumor-promoting phorbol esters on PGE2 and 
adenosine receptor-mediated CAMP accumulation 
in a single line, Jurkat, we found that this dif- 
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ference was due not to 
to differences in which 
2. EXPERIMENTAL 
2.1. Cell culture 
FEBS 
differences in cell line but 
receptor was activated. 
The human T-cell leukemia cell line Jurkat was 
cultivated in RPMI-1640 supplemented with 7.5% 
fetal calf serum, 2 mM L-glutamine and an- 
tibiotics in a humidified incubator (37”C, 95% 
02/5% CO2) at a cell density of 0.5 x lO”/ml for 
24 h before the assay. 
2.2. Assay conditions 
In all experiments the phosphodiesterase in- 
hibitor rolipram was added to a final concentra- 
tion of 30pM, since it was found to block 
adequately the CAMP breakdown without interfer- 
ing with adenosine receptors [13]. The incubations 
were performed in a shaking water bath (37°C) for 
10 min in Hepes-buffered RPMI-1640 without 
fetal calf serum and terminated by the addition of 
PCA. Protein was removed by centrifugation and 
the CAMP content in the neutralized supernatants 
was determined with a protein binding assay [ 141. 
3. RESULTS 
Incubation of Jurkat cells with the adenosine 
analogue NECA induced a concentration- 
dependent accumulation of CAMP (fig.1). Max- 
imal accumulation was obtained at lo-IOOpM 
NECA. PGEz was more potent than NECA as a 
stimulator of CAMP formation (approx. lOO-fold), 
but the maximal effect was smaller. 
PDiBu alone had no effect on CAMP accumula- 
tion, but if added together with NECA the ac- 
cumulation of CAMP was markedly potentiated. 
The highest concentration of NECA (100 FM), 
which alone produced a 9-fold increase of CAMP, 
increased the CAMP accumulation 16-fold in the 
presence of 100 nM PDiBu. The relative potentia- 
tion was 78% at 1OpM and 70% at 1OOpM 
NECA. 
The opposite effect was seen when PDiBu was 
added together with PGE2. The effect of 1 PM 
PGEz was reduced from 29.8 pmol CAMP per 10” 
cells to 14.2, i.e. a reduction by 52%. The maximal 
effect of the phorbol ester was seen together with 
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Fig. 1. The effect of phorbol ester (PDiBu) on adenosine 
and prostaglandin receptor-mediated stimulation of 
CAMP accumulation in Jurkat cells. Jurkat cells were 
incubated for 10 min at 37°C in a shaking water bath 
with NECA (O-lOOpM, circles) or PGEz (O-1000 nM, 
squares) in the presence of PDiBu (100 nM, open 
symbols) or vehicle (0.001% ethanol, closed symbols). 
Mean and SE from 6-9 determinations. 
the second highest concentration of PGEz 
(100 nM) where the reduction was 69%. 
The potentiating and inhibiting effects of phor- 
bol esters (fig.2) were further investigated by com- 
paring different concentrations of the two 
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Fig.2. Dose-dependent effect of phorbol esters on PGEz- 
and NECA-induced CAMP accumulation. incubation 
conditions as described in the legend to fig.1. NECA 
10,~M (open symbols), PCEl (filled symbols), PDiBu 
(triangles), TPA (squares), 4~PDD (circles). Mean and 
SE from 3-9 determinations. The effects of TPA and 
PDiBu at concentrations above 1 nM on PGEz- and 
NECA-induced cAMP accumulation were statistically 
significant (p < 0.05, or better) by Student’s I-test. 
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Fig.3. Effect of 100 nM PDiBu on the synergistic 
interaction between NECA (10 PM), PGEz (1 ,uM) and 
forskolin (0.3 PM). Mean and SE from 3 
determinations. Statistical hypotheses were tested by 
Student’s t-test. 
tumor-promoting and PK-C-activating phorbol 
esters, PDiBu and TPA, with the inactive &-PDD 
[7]. Both PDiBu and TPA significantly increased 
NECA-stimulated CAMP accumulation and 
significantly decreased POE*-induced CAMP pro- 
duction already at 1 nM (p < O.OS), whereas 4cu- 
PDD at 1000 nM was totally ineffective. The effect 
of TPA and PDiBu was also dose-dependent over 
the range l-1000 nM. PDiBu appeared to be more 
effective than TPA as described earlier [3,12]. 
Forskolin at 0.3 FM had no effect on CAMP 
levels in the absence of added agonists, but if add- 
ed together with NECA and PGE2 a clear 
synergism was seen (fig.3) as described in other 
systems [15,16]. The effect of 1OpM NECA was 
increased by 178% and that of 1 PM PGEz by 
241%. When 100 nM PDiBu was added together 
with 10pM NECA and 0.3 FM forskolin, the 
CAMP response was 228% of that observed with 
NECA alone. Together with 1 PM PGE2 and 
0.3 PM forskolin the effect of 100 nM PDiBu was 
inhibitory, as in the absence of forskolin. The 
CAMP accumulation was clearly higher than with 
PGE2 alone, but the potentiation was only 99%. 
Thus, the phorbol ester had reduced the response 
by more than 50%. 
4. DISCUSSION 
The important finding of the present study is 
that activation of PK-C by phorbol esters can 
modulate receptor-stimulated accumulation of 
CAMP in opposite ways depending on which recep- 
tor is being stimulated. Thus, the contradictory ef- 
fects in the literature regarding the effect of PK-C 
activation on CAMP accumulation induced by 
adenosine analogues and PGE2 [5,12,13,17] could 
be confirmed and extended by the present finding 
that even in the same cell the effect of PGE2 was 
inhibited and that of adenosine was stimulated. 
Such differential receptor-receptor interactions are 
of potential biological significance. 
The present data are also relevant for our 
understanding of how these interactions between 
phorbol esters and receptor-activated CAMP ac- 
cumulation are brought about. Since the effects of 
PGEz and NECA were altered in opposite direc- 
tions, the mechanism could not involve an interac- 
tion at a step that is common for the two receptor 
pathways. The potentiation of both the NECA and 
PGE2 effects by a low dose of forskolin indicates 
that both types of receptors activate the adenylate 
cyclase in similar ways [ 151. Thus, neither a direct 
effect on adenylate cyclase nor an effect of the in- 
teraction between N,cr (Gs~) and adenylate cyclase 
can adequately explain the findings. It has been 
shown that phorbol esters stimulate the phospho- 
rylation of transferrin, insulin, somatomedin C 
and al-adrenergic receptors [ 18-201 and that phor- 
bol ester treatment significantly reduces the 
muscarinic receptor binding in cultured human 
neuroblastoma cells [21]. It is therefore an in- 
teresting possibility that the phorbol esters had 
stimulated the phosphorylation of both the adeno- 
sine and prostaglandin receptor protein and that 
this alters the way in which they interact with the 
GTP-binding protein(s) that affect adenylate 
cyclase. 
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